» Articles » PMID: 24790655

Future Directions for the Early Detection of Colorectal Cancer Recurrence

Overview
Journal J Cancer
Specialty Oncology
Date 2014 May 3
PMID 24790655
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Surgical resection remains a mainstay of treatment and is highly effective for localized colorectal cancer. However, ~30-40% of patients develop recurrence following surgery and 40-50% of recurrences are apparent within the first few years after initial surgical resection. Several variables factor into the ultimate outcome of these patients, including the extent of disease, tumor biology, and patient co-morbidities. Additionally, the time from initial treatment to the development of recurrence is strongly associated with overall survival, particularly in patients who recur within one year of their surgical resection. Current post-resection surveillance strategies involve physical examination, laboratory, endoscopic and imaging studies utilizing various high and low-intensity protocols. Ultimately, the goal is to detect recurrence as early as possible, and ideally in the asymptomatic localized phase, to allow initiation of treatment that may still result in cure. While current strategies have been effective, several efforts are evolving to improve our ability to identify recurrent disease at its earliest phase. Our aim with this article is to briefly review the options available and, more importantly, examine emerging and future options to assist in the early detection of colon and rectal cancer recurrence.

Citing Articles

The Erosion of Healthcare and Scientific Integrity: A Growing Concern.

Brucher B J Healthc Leadersh. 2025; 17:23-43.

PMID: 40007855 PMC: 11853952. DOI: 10.2147/JHL.S506767.


Preoperative Carcinoembryonic Antigen as a Predictor of 5-Year Survival in Rectal Cancer: Proposing a New Prognostic Cutoff.

Keshvari A, Ahmadi Tafti S, Keramati M, Fazeli M, Kazemeini A, Behboudi B J Gastrointest Cancer. 2025; 56(1):46.

PMID: 39826023 DOI: 10.1007/s12029-025-01175-2.


The Impact of potential 'confounders' on the diagnostic sensitivity of circulating free DNA in management of FIT+ patients: a pilot study.

Scimia M, Pepe F, Russo G, Palumbo L, Malapelle U, Chuang R J Clin Pathol. 2024; 77(8):557-560.

PMID: 38649261 PMC: 11287558. DOI: 10.1136/jcp-2024-209527.


Novel applications of histopathological markers to distinguish prognostic subgroups in colorectal adenocarcinoma.

Yuan Y, Ren W, Zhu J, Ji S, Yang Q Ann Med. 2023; 55(2):2244181.

PMID: 37557892 PMC: 10413918. DOI: 10.1080/07853890.2023.2244181.


Plasma Exosome Gene Signature Differentiates Colon Cancer from Healthy Controls.

Vallejos P, Gonda A, Yu J, Sullivan B, Ostowari A, Kwong M Ann Surg Oncol. 2023; 30(6):3833-3844.

PMID: 36864326 PMC: 10175396. DOI: 10.1245/s10434-023-13219-7.


References
1.
Delanote V, Vandekerckhove J, Gettemans J . Plastins: versatile modulators of actin organization in (patho)physiological cellular processes. Acta Pharmacol Sin. 2005; 26(7):769-79. DOI: 10.1111/j.1745-7254.2005.00145.x. View

2.
Chang G, Kaiser A, Mills S, Rafferty J, Buie W . Practice parameters for the management of colon cancer. Dis Colon Rectum. 2012; 55(8):831-43. DOI: 10.1097/DCR.0b013e3182567e13. View

3.
Goldstein M, Mitchell E . Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005; 23(4):338-51. DOI: 10.1081/cnv-58878. View

4.
Trivedi P, Braden B . Indications, stains and techniques in chromoendoscopy. QJM. 2012; 106(2):117-31. PMC: 3550597. DOI: 10.1093/qjmed/hcs186. View

5.
Cortet M, Grimault A, Cheynel N, Lepage C, Bouvier A, Faivre J . Patterns of recurrence of obstructing colon cancers after surgery for cure: a population-based study. Colorectal Dis. 2013; 15(9):1100-6. DOI: 10.1111/codi.12268. View